alagebrium has been researched along with Peripheral Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scuteri, A | 1 |
| Capriotti, A; Clattenburg, L; Corretti, MC; Gerstenblith, G; Kass, DA; Melenovsky, V; Zieman, SJ | 1 |
1 trial(s) available for alagebrium and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Topics: Aged; Aging; Blood Pressure; Carotid Arteries; Collagen; Elasticity; Endothelium, Vascular; Female; Glycation End Products, Advanced; Humans; Hypertension; Intercellular Adhesion Molecule-1; Male; Manometry; Matrix Metalloproteinase 9; Middle Aged; Peripheral Vascular Diseases; Single-Blind Method; Thiazoles; Transforming Growth Factor beta1; Vascular Cell Adhesion Molecule-1; Vasodilation | 2007 |
1 other study(ies) available for alagebrium and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Slowing arterial aging: how far have we progressed?
Topics: Aging; Blood Pressure; Glycation End Products, Advanced; Humans; Hypertension; Peripheral Vascular Diseases; Thiazoles | 2007 |